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demonstrate that mutant MGMT after an IRES facilitates the
selection of cells expressing a gene that is therapeutic for a
human disease. This model should be useful for gene therapy of
human LAD, and may be a prototype for gene therapy for other
single gene defects.
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The immunological graft-versus-tumor (GVT) effect has been
reported in various solid cancers after allogeneic hematopoietic
stem cell transplantation (HSCT). We evaluated the experience
of allogeneic HSCT for renal cell carcinoma (RCC) in Europe.
Methods and Patients: We report the data on 124 patients
with clear cell RCC, median age 52 years (range 18-68) trans-
planted in 21 European centers. Various reduced intensity con-
ditionings (RIC) based on ﬂudarabine were used. All patients
received allogeneic peripheral blood cells: 106 from an HLA-
identical sibling, 5 from mismatched related donor and 13 from
matched unrelated donor (MUD). GVHD prophylaxis consisted
of cyclosporine A (CyA) alone, or combined with methotrexate
or mycophenolate mofetil. All patients with mismatch or MUD
received anti-T-lymphocyte immunoglobulin. Donor lympho-
cyte infusions (DLI) were given to 42 patients. The median
follow-up was 15 months (range 3-41). Results: All but 3
patients engrafted. The cumulative incidence of grades II-IV
acute graft-versus-host disease (GVHD) was 40% and for
chronic GVHD it was 33%. Transplant-related mortality was
16% at one year. Complete (n  4) or partial (n  24) responses,
median 150 (range 42-600) days posttransplant, were associated
with time from diagnosis to HSCT, mismatched donor and
acute GVHD II-IV. Factors associated with survival included
chronic GVHD (hazards ratio, HR 4.12, P  .001), DLI (HR
3.39, P  .001), 3 metastatic sites (HR 2.61, P  .002) and a
Karnofsky score 	70 (HR 2.33, P  .03). Patients with chronic
GVHD and given DLI (n  17) had a 2-year survival of 70%.
Conclusions: Our data demonstrate that i) RCC patients with
less than 3 metastatic locations and a Karnofsky score 	70%
may be considered for HSCT, ii) RIC and allogeneic HSCT is
feasible in RCC patients with a low non-progression-mortality
(16%), iii) a clinically meaningful GVT effect can be generat-
ed in these patients, often associated to DLI and chronic
GVHD.
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GENE EXPRESSION ANALYSIS OF CIRCULATING HEMATOPOIETIC PRO-
GENITOR CELLS FROM IRRADIATED MICE AND HUMANS PROVIDES A
MOLECULAR PROFILE OF RADIATION INJURY
Chute, J.P., Muramoto, G., Dressman, H., Chao, N.J., Nevins, J. Duke
University, Durham, NC.
The risk for terrorist-mediated nuclear or radiological attack has
been identiﬁed as a major threat to the United States in the coming
decade. Radiation exposure can cause a spectrum of hematological
toxicities, from mild immunosuppression to myeloablation with
concordant life threatening complications. Accurate biological do-
simetry will be critical, therefore, for caregivers to triage individ-
uals to the appropriate medical management. Currently, biodosi-
metric tools include lymphocyte depletion kinetic and cytogenetic
analysis, both of which require several days for results to be ob-
tained. We propose that high throughput genomic analysis of
peripheral blood mononuclear cells (PB MNCs) can sensitively
identify patterns of molecular changes which occur following dif-
ferent levels of radiation exposure. In this study, we collected
primary PB MNCs from 10 week old C57Bl6 mice at 6 hours
following 4 different levels of radiation exposure: normal (non-
irradiated), 50 cGy (trivial exposure), 200 cGy (myelosuppressive)
and 1000 cGy (lethal). RNA was extracted and used for synthesis of
probes for hybridization to spotted arrays. We performed a binary
regression analysis to elucidate patterns of gene expression to
distinguish between a normal animal and one that had been ex-
posed to various levels of radiation. Distinct gene expression pat-
terns were evident within PB MNCs at each of the 4 exposure
levels, demonstrating the feasibility of this approach. We found
that the selected metagene pattern for “normal” was able to dis-
tinguish normal from 50 cGy, 200 cGy and 1000 cGy exposure
with 100% predictive capacity. The predictors selected for 50 cGy,
200 cGy and 1000 cGy were equally powerful at distinguishing
these levels of exposure from all others. These data demonstrate
the power of this approach to correctly distinguish clinically rele-
vant levels of radiation exposure. In order to validate these molec-
ular predictors generated in mice as proﬁles of human radiation
response, we are currently testing, in a blinded manner, whether
these predictors can distinguish different levels of radiation expo-
sure in human PB samples collected from patients who have un-
dergone 200 cGy or 1000 cGy total body irradiation. These vali-
dated biomarkers of radiation response can serve as templates for
rapid screening tests for radiation exposure and, more broadly, are
potential targets for therapeutic intervention.
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